Literature DB >> 1370678

Recessive dystrophic epidermolysis bullosa phenotype is preserved in xenografts using SCID mice: development of an experimental in vivo model.

Y H Kim1, D T Woodley, K C Wynn, W Giomi, E A Bauer.   

Abstract

Recessive dystrophic epidermolysis bullosa (RDEB) is a subgroup of hereditary blistering diseases characterized by repetitive wounding and healing with subsequent extensive scarring. The purpose of this study was to establish a xenograft model that retains the RDEB phenotype and thus might be used as an experimental in vivo model to explore the molecular and biochemical mechanisms of the chronically wounded phenotype of RDEB. Full-thickness, tumor-free RDEB skin tissues were grafted onto the dorsum of severe combined immunodeficiency (SCID) mice. At 4, 8, 12, and 24 weeks after grafting, the xenografts were removed for examination. Immunofluorescence studies were performed using species-specific antibodies to human class I antigen, mouse class I antigen, human type IV and VII collagens and with cross-reacting antibody against bullous pemphigoid antigen (BPA). Staining with the antibody to human class I antigen, W6/32, and with the antibody to mouse class I antigen, 20.8.4s, confirmed the species-specific results obtained with the type IV and type VII collagen and laminin antibodies. The RDEB grafts showed essentially no staining with the type VII collagen antibody. Antibodies against laminin and BPA showed normal staining patterns in RDEB grafts. There was an overall paucity of anchoring fibrils in the grafts when examined with electron microscopy. Blisters could be induced in these grafts with minor trauma and showed a sublamina densa separation by immunomapping and electron microscopy. As late as 24 weeks post-transplantation, the RDEB grafts remain human, are not significantly replaced by mouse cells, and retain the RDEB disease phenotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370678     DOI: 10.1111/1523-1747.ep12555849

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  13 in total

Review 1.  Gene therapy for a lethal genetic blistering disease: a status report.

Authors:  E A Bauer; G S Herron; M P Marinkovich; P A Khavari; A T Lane
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

2.  Engraftment of precursor lesions of human cutaneous neoplasms onto C.B-17 SCID mice: a useful in vivo experimental model of carcinogenesis in human skin.

Authors:  Y Takizawa; T Saida; Y Tokuda; S Dohi; S Ikegawa; Y Ueyama
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

3.  SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.

Authors:  Matthias Titeux; Valérie Pendaries; Maria A Zanta-Boussif; Audrey Décha; Nathalie Pironon; Laure Tonasso; José E Mejia; Agnes Brice; Olivier Danos; Alain Hovnanian
Journal:  Mol Ther       Date:  2010-05-18       Impact factor: 11.454

4.  In vivo targeting of integrin receptors in human skin xenografts by intravenously applied antibodies.

Authors:  R Kaufmann; A Hainzl; W Sterry; S Alberti; C E Klein
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

5.  Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue.

Authors:  Susana Ortiz-Urda; Qun Lin; Cheryl L Green; Douglas R Keene; M Peter Marinkovich; Paul A Khavari
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

6.  Tuberculin-induced delayed-type hypersensitivity reaction in a model of hu-PBMC-SCID mice grafted with autologous skin.

Authors:  A Tsicopoulos; J Pestel; O Fahy; H Vorng; F Vandenbusche; H Porte; L Eraldi; A Wurtz; H Akoum; Q Hamid; B Wallaert; A B Tonnel
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

7.  Human/severe combined immunodeficient mouse chimeras. An experimental in vivo model system to study the regulation of human endothelial cell-leukocyte adhesion molecules.

Authors:  H C Yan; I Juhasz; J Pilewski; G F Murphy; M Herlyn; S M Albelda
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

8.  Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa.

Authors:  J C Lapiere; D T Woodley; M G Parente; T Iwasaki; K C Wynn; A M Christiano; J Uitto
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure.

Authors:  Xinyi Wang; Pedram Ghasri; Mahsa Amir; Brian Hwang; Yingpin Hou; Michael Khalili; Michael Khilili; Andrew Lin; Douglas Keene; Jouni Uitto; David T Woodley; Mei Chen
Journal:  Mol Ther       Date:  2013-05-14       Impact factor: 11.454

10.  Development of pemphigus vulgaris-like lesions in severe combined immunodeficiency disease mice reconstituted with lymphocytes from patients.

Authors:  I Juhasz; G S Lazarus; G F Murphy; I M Shih; M Herlyn
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.